A5011726172- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
- Acute Lymphoblastic Leukemia research
- CNS Lymphoma Diagnosis and Treatment
- Speech and dialogue systems
- Cancer Treatment and Pharmacology
- Speech Recognition and Synthesis
- Histone Deacetylase Inhibitors Research
- Advanced Breast Cancer Therapies
- Frailty in Older Adults
- Immune Cell Function and Interaction
- Immune cells in cancer
- Speech and Audio Processing
- Multiple Myeloma Research and Treatments
- Hemoglobinopathies and Related Disorders
- Protein Degradation and Inhibitors
- Breast Cancer Treatment Studies
- Palliative Care and End-of-Life Issues
- Single-cell and spatial transcriptomics
University of Pennsylvania
2011-2025
University of Edinburgh
2022-2025
Hospital of the University of Pennsylvania
2023-2024
MedStar Georgetown University Hospital
2019-2024
Georgetown University
2018-2024
National Heart Lung and Blood Institute
2015-2024
National Institutes of Health
2013-2024
Pennsylvania Hospital
2024
University of Pennsylvania Health System
2024
Gilead Sciences (United States)
2023-2024
New techniques for single-cell analysis have led to insights into hematopoiesis and the immune system, but ability of these cross-validate reproducibly identify biological variation in diverse human samples is currently unproven. We therefore performed a comprehensive assessment bone marrow cells using both RNA sequencing multiparameter flow cytometry from 20 healthy adult donors across broad age range. These data characterize between as well age-associated changes cell population...
Abstract Somatic TP53 mutations and 17p deletions with genomic loss of occur in 37% to 46% acute myeloid leukemia (AML) adverse-risk cytogenetics correlate primary induction failure, high risk relapse, dismal prognosis. Herein, we aimed characterize the immune landscape TP53-mutated AML determine whether abnormalities identify a patient subgroup that may benefit from immunotherapy flotetuzumab, an investigational CD123 × CD3 bispecific dual-affinity retargeting antibody (DART) molecule. The...
Summary To evaluate the association between haemoglobinuria and chronic kidney disease ( CKD ) in sickle cell anaemia SCA ), we analysed 356 adult haemoglobin SS or Sβ o thalassaemia patients from University of Illinois at Chicago UIC 439 multi‐centre Walk‐Treatment Pulmonary Hypertension Sickle Cell Disease with Sildenafil Therapy (Walk‐ PH a SST cohort. was classified according to National Kidney Foundation Outcomes Quality Initiatives guidelines. Haemoglobinuria, defined as positive haem...
Background The powerful ‘graft versus leukemia’ effect thought partly responsible for the therapeutic of allogeneic hematopoietic cell transplantation in acute myeloid leukemia (AML) provides rationale investigation immune-based therapies this high-risk blood cancer. There is considerable preclinical evidence potential synergy between PD-1 immune checkpoint blockade and hypomethylating agents already commonly used disease. Methods We report here results 17 H-0026 (PD-AML, NCT02996474 ), an...
Abstract Intensive chemotherapy with cytarabine and anthracycline (7&3) remains the standard therapy for patients medically fit induction, but assessment of fitness controversial. Venetoclax hypomethylating agent (ven/HMA) combination has improved outcomes in unfit no prospective study assessed ven/HMA versus 7&3 as initial older, patients. Given studies expectation use outside trial criteria, we evaluated retrospective among newly diagnosed A nationwide electronic health record...
Background.Delirium is a common syndrome affecting older people in hospital, whose pathophysiology poorly understood, but sequelae of increased cognitive and functional impairment suggest neuronal loss.
Abstract Acute myeloid leukemia (AML) is a genetically heterogeneous disease that characterized by abnormal clonal proliferation of progenitor cells found predominantly within the bone marrow (BM) and blood. Recent studies suggest genetic phenotypic alterations in BM microenvironment support leukemogenesis allow leukemic to survive evade chemotherapy-induced death. However, despite substantial evidence indicating role tumor–host interactions AML pathogenesis, little known about complex BM....
Abstract Genetic mutations associated with acute myeloid leukemia (AML) also occur in age-related clonal hematopoiesis, often the same individual. This makes confident assignment of detected variants to malignancy challenging. The issue is particularly crucial for AML posttreatment measurable residual disease monitoring, where results can be discordant between genetic sequencing and flow cytometry. We show here that it possible distinguish from hematopoiesis resolve immunophenotypic identity...
Older age and poor performance status lead to worse outcomes in acute myeloid leukemia (AML) patients. Hypoalbuminemia is a negative predictor of morbidity mortality several malignancies. We evaluated the relationship between baseline serum albumin levels on treatment-related complications, as well short-term overall survival (OS) 756 newly diagnosed AML conducted retrospective multicenter study examine complications OS according pretreatment levels: normal ≥3.5 g/dl, marked hypoalbuminemia...